PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: sales force
GSK Reps Trade Sales Targets for Sales Competencies
Last summer, GlaxoSmithKline announced plans to upend the pay structure for its US-based sales reps by removing incentives based on hard sales figures, or how many pills are sold. Instead of rewarding reps for the amount of product sold, GSK would begin rewarding reps for the quality of relationship they engender, the company said.
Shrinks Like Latuda Over the Competition, Survey Finds
Psychiatrists are more likely to recommend Sunovion Pharmaceuticals’ Latuda to colleagues than Merck’s Saphris or Novartis’ Fenapt, according to a DTW Marketing Research survey.
All three drugs are atypical antipsychotics indicated for schizophrenia, and had US launches in late 2009 (Saphris), early 2010 (Fenapt) and February of this year (Latuda). Latuda, however, appears to be gaining [...]
Lilly Sales Force Buyouts Revealed
Image via Wikipedia
Lilly, on Tuesday, announced that it will offer 4,000 sales reps a buyout in hopes of reducing its sales force by 300 before year’s end. According to a Lilly spokesperson, this is a voluntary exit program for eligible sales force professionals in its diabetes, neuroscience, and osteoporosis business units. Reps have the opportunity [...]
GSK Signs $120M Deal to Market DMab Overseas
Image via Wikipedia
In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval.
GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]
Posted in Deals, News, Technology Also tagged Amgen, Australia, Canada, denosumab, Dmab, GlaxoSmithKline, Market, Mexico, New Zealand, U.S. Food and Drug Administration, United States 1 Comment
Sales Rep vs. eDetail: Consider the Practice Area